Related Experiment Video
Updated: Jun 15, 2026
06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
Therapeutic directions for Parkinson's disease
1Department of Neurology, University of Rochester, Rochester, New York 14620, USA. ira.shoulson@ctcc.rochester.edu
Movement Disorders : Official Journal of the Movement Disorder Society
|February 27, 2010
Summary
Large clinical trials for Parkinson's disease (PD) revealed a significant link between uric acid levels and disease progression. Continued follow-up provides valuable insights into PD
Area of Science:
- Neurology
- Clinical Trials
- Biomarkers
Background:
- Focus on disease-modifying treatments for Parkinson's disease (PD) may overshadow incremental gains.
- Large multi-center clinical trials are crucial for advancing PD knowledge.
- Unforeseen discoveries can emerge from rigorous clinical research.
Purpose of the Study:
- To highlight the value of incremental gains in Parkinson's disease research.
- To emphasize the importance of large clinical trials like DATATOP and PRECEPT.
- To underscore the significance of post-trial cohort follow-up for understanding PD.
Main Methods:
- Utilizing data from large multi-center clinical trials (e.g., DATATOP, PRECEPT).
- Conducting systematic follow-up of clinical trial cohorts post-intervention.
- Employing data mining, public reporting, and data sharing.
Main Results:
- Established and confirmed an unforeseen relationship between circulating uric acid and PD occurrence/progression.
- Demonstrated the added value of systematic follow-up for understanding PD natural history.
- Identified potential state and trait biomarkers and genotype-phenotype relationships.
Conclusions:
- Incremental gains and unexpected findings, like the uric acid-PD link, are vital in PD research.
- Continued analysis of clinical trial cohorts offers enduring insights into Parkinson's disease.
- Data sharing and mining enhance the value derived from clinical trial data.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...